Siegfried Schmitt, vice president, Technical at Parexel, comments on the new paradigm of remote audits.
Because of the COVID-19 pandemic, many companies no longer permit on-site audits. This has many advantages for the audited company (the auditee). This article tells how a company could explore this opportunity to its maximum advantage.
In order to make customer audits as efficient and effective for us, we have decided to update the respective standard operating procedure. Here we summarize the key elements:
Audits can be so much more relaxed and enjoyable because virtual audits have become commonplace. If this memo seems familiar, then this is pure coincidence.
Siegfried Schmitt is vice president, Technical at Parexel.
BioPharm International
Volume 34, Number 11
November 2021
Page: 46
When referring to this article, please cite it as S. Schmitt, “The Remote Audit–A Tongue-in-Cheek Memo,” BioPharm International 34 (11) 2021.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.